retatrutide approval status october 2025 for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Quarterly Drug Pipeline: October 2025

METAL: fast and efficient meta-analysis of genomewide association scans

Clinically meaningful reductions were observed in triglycerides, remnant cholesterol, and liver fat with favorable safety and tolerability

The decision should be based on your personal schedule and when you feel most prepared to manage potential side effects

When engaged, the receptor initiates cascades that influence metabolism, inflammation, cell survival, and neural activity

8,129,343 protects the chemical structure of the semaglutide molecule, meaning no one else is allowed to manufacture that specific sequence of amino acids until the patent expires in December 2031

The prevalence of these effects is currently unknown, and they are not commonly listed as adverse effects in US prescribing information for most agents